Published in Elife on April 02, 2013
Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell (2015) 1.58
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol (2014) 0.97
Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe (2015) 0.95
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis (2013) 0.94
Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. J Virol (2014) 0.94
A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol (2013) 0.92
Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol (2014) 0.90
Early Events in Chikungunya Virus Infection-From Virus CellBinding to Membrane Fusion. Viruses (2015) 0.89
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. J Infect Dis (2016) 0.83
Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proc Natl Acad Sci U S A (2015) 0.81
Residue-level resolution of alphavirus envelope protein interactions in pH-dependent fusion. Proc Natl Acad Sci U S A (2015) 0.80
Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Rep (2015) 0.80
Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. PLoS One (2014) 0.79
Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. J Virol (2015) 0.78
Single-residue posttranslational modification sites at the N-terminus, C-terminus or in-between: To be or not to be exposed for enzyme access. Proteomics (2015) 0.76
Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms. Clin Vaccine Immunol (2016) 0.76
Development of Vaccines for Chikungunya Fever. J Infect Dis (2016) 0.76
Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Cell Rep (2016) 0.76
A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. J Infect Dis (2016) 0.75
Assembly, maturation and three-dimensional helical structure of the teratogenic rubella virus. PLoS Pathog (2017) 0.75
Dissecting Virus Infectious Cycles by Cryo-Electron Microscopy. PLoS Pathog (2016) 0.75
A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med (2016) 0.75
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature (1992) 36.50
EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol (1999) 27.52
EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol (2006) 14.70
A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog (2007) 10.38
Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol (2007) 6.16
Super-resolution biomolecular crystallography with low-resolution data. Nature (2010) 6.14
Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics. Structure (2008) 5.97
FREALIGN: high-resolution refinement of single particle structures. J Struct Biol (2006) 5.85
Visualizing density maps with UCSF Chimera. J Struct Biol (2006) 5.75
The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell (2001) 5.65
An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg (1955) 4.94
Structure of Sindbis virus core protein reveals a chymotrypsin-like serine proteinase and the organization of the virion. Nature (1991) 4.24
Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol (2006) 4.16
Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature (2004) 4.02
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol (1998) 3.51
Protein structure fitting and refinement guided by cryo-EM density. Structure (2008) 3.12
Combining electron microscopic with x-ray crystallographic structures. J Struct Biol (2001) 3.07
Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold. Cell (2001) 2.96
Evidence for specificity in the encapsidation of Sindbis virus RNAs. J Virol (1989) 2.91
Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature (2010) 2.90
Placement of the structural proteins in Sindbis virus. J Virol (2002) 2.81
Normal mode based flexible fitting of high-resolution structure into low-resolution experimental data from cryo-EM. J Struct Biol (2004) 2.78
Three-dimensional structure of a membrane-containing virus. Proc Natl Acad Sci U S A (1993) 2.71
Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. J Virol (1993) 2.69
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology (2000) 2.59
Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis (2009) 2.54
Membrane fusion process of Semliki Forest virus. I: Low pH-induced rearrangement in spike protein quaternary structure precedes virus penetration into cells. J Cell Biol (1992) 2.51
Identification of a protein binding site on the surface of the alphavirus nucleocapsid and its implication in virus assembly. Structure (1996) 2.46
Structural changes of envelope proteins during alphavirus fusion. Nature (2010) 2.32
Site-directed mutations in Sindbis virus E2 glycoprotein's cytoplasmic domain and the 6K protein lead to similar defects in virus assembly and budding. Virology (1991) 2.14
Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology (1991) 2.13
Aromatic interactions define the binding of the alphavirus spike to its nucleocapsid. Structure (1996) 2.12
Site-directed mutagenesis of the proposed catalytic amino acids of the Sindbis virus capsid protein autoprotease. J Virol (1990) 2.11
A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. J Gen Virol (2008) 2.05
Quantitative fitting of atomic models into observed densities derived by electron microscopy. J Struct Biol (1999) 2.02
Identification of a region in the Sindbis virus nucleocapsid protein that is involved in specificity of RNA encapsidation. J Virol (1996) 1.96
Fitting of high-resolution structures into electron microscopy reconstruction images. Structure (2005) 1.85
Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc Natl Acad Sci U S A (1995) 1.81
4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J (2011) 1.77
A comparison of the heme binding pocket in globins and cytochrome b5. J Biol Chem (1975) 1.74
Structure of Semliki Forest virus core protein. Proteins (1997) 1.70
Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am (2008) 1.69
Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res (2008) 1.64
Interpretation of electron density with stereographic roadmap projections. J Struct Biol (2006) 1.64
Replication cycle of chikungunya: a re-emerging arbovirus. Virology (2009) 1.61
Alphavirus budding is dependent on the interaction between the nucleocapsid and hydrophobic amino acids on the cytoplasmic domain of the E2 envelope glycoprotein. Virology (1997) 1.61
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
In vitro assembly of alphavirus cores by using nucleocapsid protein expressed in Escherichia coli. J Virol (1999) 1.54
Membrane structure and interactions with protein and DNA in bacteriophage PRD1. Nature (2004) 1.53
Alphavirus nucleocapsid protein contains a putative coiled coil alpha-helix important for core assembly. J Virol (2001) 1.46
The Sindbis virus 6K protein can be detected in virions and is acylated with fatty acids. Virology (1990) 1.44
Structural rearrangement of infecting Sindbis virions at the cell surface: mapping of newly accessible epitopes. J Virol (1993) 1.34
The organization of the spike complex of Semliki Forest virus. J Mol Biol (1994) 1.30
Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells. J Virol (1993) 1.25
Nucleic acid-dependent cross-linking of the nucleocapsid protein of Sindbis virus. J Virol (2000) 1.25
Heparan sulfate binding can contribute to the neurovirulence of neuroadapted and nonneuroadapted Sindbis viruses. J Virol (2007) 1.24
Resolution-adapted recombination of structural features significantly improves sampling in restraint-guided structure calculation. Proteins (2012) 1.21
Structural proteins of Chikungunya virus. J Virol (1984) 1.18
Heparin binding sites on Ross River virus revealed by electron cryo-microscopy. Virology (2005) 1.18
Involvement of the molecular chaperone BiP in maturation of Sindbis virus envelope glycoproteins. J Virol (1995) 1.13
Determining macromolecular assembly structures by molecular docking and fitting into an electron density map. Proteins (2010) 1.10
A single mutation in the E2 glycoprotein important for neurovirulence influences binding of sindbis virus to neuroblastoma cells. J Virol (2002) 1.07
Role of glycoprotein PE2 in formation and maturation of the Sindbis virus spike. J Virol (1997) 1.04
Genetic determinants of Sindbis virus strain TR339 affecting midgut infection in the mosquito Aedes aegypti. J Gen Virol (2007) 1.03
Building and refining protein models within cryo-electron microscopy density maps based on homology modeling and multiscale structure refinement. J Mol Biol (2010) 1.03
Genetic determinants of Sindbis virus mosquito infection are associated with a highly conserved alphavirus and flavivirus envelope sequence. J Virol (2007) 1.03
Alphavirus capsid protein helix I controls a checkpoint in nucleocapsid core assembly. J Virol (2006) 1.01
Role of antibodies in controlling alphavirus infection of neurons. Curr Top Microbiol Immunol (2001) 1.00
The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis (2010) 0.99
Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus budding. J Virol (2010) 0.95
The structure of barmah forest virus as revealed by cryo-electron microscopy at a 6-angstrom resolution has detailed transmembrane protein architecture and interactions. J Virol (2011) 0.95
Sindbis virus nucleocapsid assembly: RNA folding promotes capsid protein dimerization. RNA (2004) 0.95
Sindbis virus conformational changes induced by a neutralizing anti-E1 monoclonal antibody. J Virol (2008) 0.93
Reconstructing virus structures from nanometer to near-atomic resolutions with cryo-electron microscopy and tomography. Adv Exp Med Biol (2012) 0.93
Glycosaminoglycan binding properties of natural venezuelan equine encephalitis virus isolates. J Virol (2003) 0.91
The structure determination of Sindbis virus core protein using isomorphous replacement and molecular replacement averaging between two crystal forms. Acta Crystallogr A (1992) 0.90
Practical procedure for coma-free alignment using caustic figure. Ultramicroscopy (2003) 0.80
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 5.02
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
Outcome of the first electron microscopy validation task force meeting. Structure (2012) 4.35
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol (2003) 4.11
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
Structure of West Nile virus. Science (2003) 3.48
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
Structure of the cell-puncturing device of bacteriophage T4. Nature (2002) 3.32
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Three-dimensional rearrangement of proteins in the tail of bacteriophage T4 on infection of its host. Cell (2004) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 3.26
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
The structure of the phage T4 DNA packaging motor suggests a mechanism dependent on electrostatic forces. Cell (2008) 3.07
The structure and evolution of the major capsid protein of a large, lipid-containing DNA virus. Proc Natl Acad Sci U S A (2002) 3.07
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science (2007) 2.95
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol (2002) 2.89
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
The tail structure of bacteriophage T4 and its mechanism of contraction. Nat Struct Mol Biol (2005) 2.82
Placement of the structural proteins in Sindbis virus. J Virol (2002) 2.81
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
Conservation of the capsid structure in tailed dsDNA bacteriophages: the pseudoatomic structure of phi29. Mol Cell (2005) 2.80
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature (2003) 2.63
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
Structural and functional similarities between the capsid proteins of bacteriophages T4 and HK97 point to a common ancestry. Proc Natl Acad Sci U S A (2005) 2.53
Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms. Proc Natl Acad Sci U S A (2009) 2.52
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
Structural changes of envelope proteins during alphavirus fusion. Nature (2010) 2.32
Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther (2005) 2.32
Outcome of a workshop on archiving structural models of biological macromolecules. Structure (2006) 2.32
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25